Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Squamous non–small-cell lung cancer (NSCLC) accounts for approximately 20 to 30% of all lung cancers and is associated with shorter survival than is nonsquamous NSCLC. Historically, the lack of targetable aberrations meant that treatment for squamous NSCLC was mostly limited to cytotoxic…

https://ift.tt/2A6S49i